fbpx

Jazz Pharmaceuticals announces a new collaborative relationship with the American Heart Association to address heart disease in sleep disorders.

Jazz Pharmaceuticals announces a new collaborative relationship with the American Heart Association to address heart disease in sleep disorders.

 

Jazz Pharmaceuticals is proud to support the American Heart Association’s sleep health educational content
 

Research demonstrates that disrupted sleep and sleep disorders are associated with a higher risk of cardiovascular and cardiometabolic diseases, including obesity, diabetes, heart attack, stroke and coronary artery disease

DUBLIN, Sept. 15, 2020 /PRNewswire/ — Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced its support of the American Heart Association’s sleep health educational content aimed at improving the health and well-being of those struggling with healthy sleep or those living with sleep disorders. As part of the initiative, the Association, with financial support from Jazz, will create educational multimedia content that will be available at www.heart.org/en/health-topics/sleep-disorders.

Read More…